Informa plc (LON:INF) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Informa plc (LON:INF) have received a consensus recommendation of “Moderate Buy” from the six brokerages that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is GBX 1,093.33.

INF has been the topic of several recent analyst reports. Citigroup dropped their price objective on Informa from GBX 1,000 to GBX 850 and set a “neutral” rating on the stock in a research note on Thursday, April 9th. JPMorgan Chase & Co. reduced their target price on shares of Informa from GBX 1,300 to GBX 1,285 and set an “overweight” rating for the company in a research note on Thursday.

Informa Stock Up 0.4%

Shares of LON:INF opened at GBX 922 on Monday. The stock has a market cap of £11.60 billion, a price-to-earnings ratio of 1,152.50, a PEG ratio of 0.75 and a beta of 0.69. The company has a quick ratio of 1.70, a current ratio of 0.44 and a debt-to-equity ratio of 61.56. Informa has a 12-month low of GBX 719 and a 12-month high of GBX 1,000. The business’s 50 day moving average is GBX 828.99 and its 200 day moving average is GBX 831.76.

Insider Transactions at Informa

In other news, insider Gareth Wright acquired 222 shares of Informa stock in a transaction on Wednesday, May 20th. The stock was acquired at an average cost of GBX 809 per share, with a total value of £1,795.98. Also, insider Stephen A. Carter acquired 222 shares of the firm’s stock in a transaction on Wednesday, May 20th. The stock was purchased at an average price of GBX 809 per share, with a total value of £1,795.98. 0.23% of the stock is owned by company insiders.

About Informa

Our events, digital products and academic research services connect specialists with knowledge, helping them learn more, know more and do more.

We do this in dozens of specialist markets and subject matter categories, including in Healthcare & Pharma, Technology, Finance, Education, Marketing, Health & Nutrition, Foodservice, and many more.

And we do this through a range of products and services, including major live events, specialist media and content, expert research articles, books and open research platforms, accredited training, buyer discovery services, and digital demand and lead-generation services.